Kapoor D, Clarke S, Stanworth R, Channer K S, Jones T H
Centre for Diabetes and Endocrinology, Barnsley NHS Foundation Trust Hospital, Barnsley, United Kingdom.
Eur J Endocrinol. 2007 May;156(5):595-602. doi: 10.1530/EJE-06-0737.
Serum testosterone levels are known to inversely correlate with insulin sensitivity and obesity in men. Furthermore, there is evidence to suggest that testosterone replacement therapy reduces insulin resistance and visceral adiposity in type 2 diabetic men. Adipocytokines are hormones secreted by adipose tissue and contribute to insulin resistance. We examined the effects of testosterone replacement treatment on various adipocytokines and C-reactive protein (CRP) in type 2 diabetic men.
Double-blinded placebo-controlled crossover study in 20 hypogonadal type 2 diabetic men. Patients were treated with testosterone (sustanon 200 mg) or placebo intramuscularly every 2 weeks for 3 months in random order followed by a washout period of 1 month before the alternate treatment phase.
Leptin, adiponectin, resistin, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and CRP levels were measured before and after each treatment phase. Body mass index (BMI) and waist circumference were also recorded.
At baseline, leptin levels significantly correlated with BMI and waist circumference. There was a significant inverse correlation between baseline IL-6 and total testosterone (r=-0.68; P=0.002) and bioavailable testosterone levels (r=-0.73; P=0.007). CRP levels also correlated significantly with total testosterone levels (r=-0.59; P=0.01). Testosterone treatment reduced leptin (-7141.9 +/- 1461.8 pg/ml; P=0.0001) and adiponectin levels (-2075.8 +/- 852.3 ng/ml; P=0.02). There was a significant reduction in waist circumference. No significant effects of testosterone therapy on resistin, TNF-alpha, IL-6 or CRP levels were observed.
Testosterone replacement treatment decreases leptin and adiponectin levels in type 2 diabetic men. Moreover, low levels of testosterone in men are associated with pro-inflammatory profile, though testosterone treatment over 3 months had no effect on inflammatory markers.
已知男性血清睾酮水平与胰岛素敏感性及肥胖呈负相关。此外,有证据表明睾酮替代疗法可降低2型糖尿病男性的胰岛素抵抗和内脏脂肪量。脂肪细胞因子是由脂肪组织分泌的激素,与胰岛素抵抗有关。我们研究了睾酮替代治疗对2型糖尿病男性各种脂肪细胞因子和C反应蛋白(CRP)的影响。
对20名性腺功能减退的2型糖尿病男性进行双盲安慰剂对照交叉研究。患者每2周接受一次睾酮(长效睾酮200mg)或安慰剂肌肉注射,为期3个月,给药顺序随机,之后有1个月的洗脱期,然后进入交替治疗阶段。
在每个治疗阶段前后测量瘦素、脂联素、抵抗素、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6和CRP水平。还记录了体重指数(BMI)和腰围。
在基线时,瘦素水平与BMI和腰围显著相关。基线IL-6与总睾酮(r=-0.68;P=0.002)及生物可利用睾酮水平(r=-0.73;P=0.007)之间存在显著负相关。CRP水平也与总睾酮水平显著相关(r=-0.59;P=0.01)。睾酮治疗可降低瘦素(-7141.9±1461.8pg/ml;P=0.0001)和脂联素水平(-2075.8±852.3ng/ml;P=0.02)。腰围显著减小。未观察到睾酮治疗对抵抗素、TNF-α、IL-6或CRP水平有显著影响。
睾酮替代治疗可降低2型糖尿病男性的瘦素和脂联素水平。此外,男性低睾酮水平与促炎状态有关,不过3个月的睾酮治疗对炎症标志物无影响。